These and other differences described ahead suggest that MDC1A and dystroglycanopathies may have some shared, but some distinct, cellular mechanisms underlying their respective CNS pathologies. This evidence concerns the gene LAMA2 and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.